linjc16/ctgov huggingface dataset:
Photodynamic Therapy (PDT) Effect on Large Surface Photodamaged Skin

Study Overview
=================
Brief Summary
-----------------
In this study, 26 patients were selected and included for full-face photodynamic therapy sessions. All patients presented signs of photoaging skin and multiple actinic keratosis. Photographs and Biopsies were taken before and after the procedure. Clinical and histological aspects as well as immunohistochemical aspects regarding neocollagen induction and tumor expression were evaluated.

Detailed Description
-----------------
Study design: Patients and methods: 26 patients (16 females, 8 males) age 35-90 years, mean 59,4 y Skin types I-IV, severely photodamaged facial skin Multiples Aks on the face ( total 268) minimum of 3 per patient Approved by local ethical committee and informed consent given Treatment procedure: Prior curettage Full-face MAL application ( Metvix ®, Galderma France) 1,5 tube per treatment Incubation time 3 hs - in the first treatment session; and 1,5 h - in the 2 nd and 3 rd sessions Illumination LED (Aktilite® Photocure, Norway) 635 nm 37 J/cm2 3 treatments performed, one month apart Pain monitoring: forced air cooling device Evaluation: Clinical - 5 point scale based on Dover's and Zane's studies Dover JS et al. Topical ALA combined with IPL in photoaging. Arch Dermatol 2005; 141: 1247-52 Zane et al. Clinical and echographical analysis of MAL- PDT in photodamaged skin. Laser Surg Med 2007; 39: 203-9 Histological - Hematoxilin- Eosin staining Immunohistochemical study- HP 53, Metalloproteinases, Procollagen I,

Official Title
-----------------
Histological and Immunohistochemical Study of Photodamaged Skin Submitted to MAL-PDT

Conditions
-----------------
Actinic Keratosis, Photoaging, Solar Elastosis

Intervention / Treatment
-----------------
* Other: Methylaminolevulinate - photodynamic therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with severe photodamage and at least 3 actinic keratosis on the face Exclusion Criteria: Pregnancy, laser, chemical peel, imiquimod or 5-Fu treatment in the last year

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Methylaminolevulinate - photodynamic therapy|Methylaminolevulinate cream 16% applied for 3 hours under occlusion on the face and then illuminated with red LED device|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Deep Venous Thrombus Characteristics and Venous Dynamics With Subsequent Thrombus Resolution and Post-thrombotic Syndrome

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to examine in vivo thrombosis characteristics with ultrasound shear wave elastography (SWE) and determine the relationship with thrombus resolution and postthrombotic syndrome (PTS) in patients with acute proximal Deep Vein Thrombosis (DVT).

Official Title
-----------------
The Relationship Between Deep Venous Thrombus Characteristics and Venous Dynamics With Subsequent Thrombus Resolution and Post-thrombotic Syndrome

Conditions
-----------------
Deep Vein Thrombosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of acute, proximal (popliteal and above) DVT with or without Pulmonary Embolism within 72 hours ≥18 Years Old Exclusion Criteria prior episode of DVT contraindication to standard therapeutic anticoagulation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thrombus Resolution | Ultrasound images of lower extremity DVTs comparing the initial diagnostic image of thrombus to a subsequent study performed after 3 months of anticoagulation.The lower extremity venous system is divided into 12 segments. Each vein segment will be analyzed on initial ultrasound and recorded 0 (no DVT), 1 (non-occlusive DVT), or 2 (occlusive DVT). The follow up ultrasound will be analyzed per vein segment and recorded as no residual thrombus, minimal chronic post-thrombotic changes, > 50% resolution, < 50% resolution, near occlusive DVT, no change, and progressive DVT. | 3 Months after diagnosis of DVT. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-thrombotic syndrome | Measured using the Villalta Score. Scale 0-33 with higher values indicating more severe symptoms. | 6 months after diagnosis of DVT | 
| Vein Specific Quality of Life | Measured using The Venous Insufficiency Epidemiological and Economic Study (VEINES) QOL survey. Scores range from 0-100 with higher scores indicating better quality of life. | 6 months after diagnosis of DVT | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thrombus Resolution, Post-Thrombotic Syndrome
Validation of a Non-invasive Hemodynamic Monitor (NexFin) in Pregnant Women

Study Overview
=================
Brief Summary
-----------------
Blood pressure and cardiac output can be measured invasively in pregnant women. Non-invasive monitoring devices are desirable, but until now, no equipment has proven validity. This study aims at validating the non-invasive monitoring device NexFin (second generation Finometer) in pregnant women.

Detailed Description
-----------------
Validation will be a direct beat-to-beat comparison of data from NexFin and the invasive measurements of blood pressure and calibrated cardiac output as an integrated part of LiDCO Plus. Both comparison of absolute values and the two different devices trending abilities will be analyzed.

Official Title
-----------------
Validation of Non-invasive Monitoring of Blood Pressure and Cardiac Output in Healthy Pregnant Women During Cesarean Section

Conditions
-----------------
Hemodynamic Changes in Pregnancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy singleton pregnancies at term scheduled for cesarean delivery Exclusion Criteria: Twins, or multiple gestation, pre-eclampsia, gestational hypertension Reynaud phenomenon

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy pregnant women<br>Healthy pregnant women for C-section under spinal anesthesia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systolic blood pressure | Comparison of beat-to-beat data | 15 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac output | Comparing beat-to-beat data of cardiac output | 15 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pregnancy, cesarean delivery, blood pressure, cardiac output
High-risk Breast Lesions: A Multicenter Retrospective Study

Study Overview
=================
Brief Summary
-----------------
In this multicenter study, the goal was to document the excisional biopsy or follow-up results of high risk lesions diagnosed on image guided CNB/VAB, and evaluate the clinical, imaging and histologic features for associated malignancy risk. The possibility of upgrade related to histologic subtype, tissue sampling and other variables was also evaluated.

Detailed Description
-----------------
This is a retrospective multicentric study that include 1345 patients from 30 centers. Patients who had a diagnosis of high risk lesions (HRL) on image guided core biopsy (tru-cut/vacuum biopsy) were reviewed in a 12 year period (between 2008 and 2020). The lesions included were ADH, LN (ALH/LCIS), papilloma (without or with atypia), RS, and FEA. The patients who managed with an excisional biopsy or having at least 1 year follow-up documentation following the diagnosis of borderline lesion were included in the study. Radiological findings, diameter of lesion (>15 vs <15 mm), needle biopsy type (14-16G vs 9-12G), sampling method and number of samplings (4 and >4 vs <4) were documented. IBM SPSS Version 25.0 statistical package program was used for analysis.

Official Title
-----------------
Outcome of High-risk Breast Lesions Diagnosed on Image-guided Core Needle Biopsy: Results From a Multicenter Retrospective Study

Conditions
-----------------
Premalignant Lesion

Participation Criteria
=================
Eligibility Criteria
-----------------
Study Population: The women with diagnosis of atypical ductal hyperplasia, lobular neoplasia, flat epithelial atypia, papilloma and radial scar on image guided core needle biopsy were studied Sampling Method: Non-Probability Sample Minimum Age: 12 Maximum Age: 86 Sex: Female Gender Based: No Accepts Healthy Volunteers: No Criteria: Inclusion Criteria: Image guided needle biopsy diagnosis Atypical ductal hyperplasia Lobular neoplasia Flat epithelial atypia Papilloma Radial scar Diagnosed on image guided needle biopsy Exclusion Criteria: Fibroepithelial tumors Mucocele like tumors Diagnosed on surgical biopsy
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| upgrade rates related to histologic subtype, tissue sampling and other variables | the results from excisional biopsy or at least 1 year follow-up documentation | one year |
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to detect recurrent bladder cancer using a combination of protein and DNA biomarkers in urine

Official Title
-----------------
Phase 3 Study of Bladder Cancer Recurrence Surveillance

Conditions
-----------------
Bladder Cancer Recurrence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Intact bladder Scheduled for cystoscopy for transitional cell bladder cancer recurrence screening Urine donated prior to cystoscopy, Bladder biopsy, chemotherapy, intravesical therapy, radiation or TUR Must be willing to sign IRB approved informed consent Exclusion Criteria: History or current diagnosis of any cancer except transitional cell bladder cancer or basal cell cancer Known diagnosis of any autoimmune disease or HIV, HCV or HBV History or current TB or any other active infection Subject has gross hematuria Receiving chemotherapy, intravesical therapy or radiation within 30 days of enrollment Any surgery except urologic within past 30 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Prevalence of Stuttering in Children With ADHD at Sohag University Hospital

Study Overview
=================
Brief Summary
-----------------
The majority of the latest research suggests that stuttering is associated with significantly elevated levels of trait and social anxiety. The prevalence of children who stutter and have attention deficit/ hyperactivity disorder (ADHD) ranges from 4 to 26%. About 10-20% of children who stutter might show ADHD. Gender ( male) is the dominant risk factor for stuttering, as also applies to other neurodevelopmental disorders. Examples include attention deficit hyperactive disorder (ADHD), conduct disorder, tics and the Gilles de la Tourette syndrome (GTS). These neurodevelopmental disorders are the second -most prominent set of comorbidities with stuttering. Attention-deficit hyperactivity disorder (ADHD) and stuttering share many characteristics in addition to temperament . A complex interplay of neural differences, with genetic and environmental components, has been reported as a possible cause of both disorders. In addition, both may appear more frequently in boys than in girls . Furthermore, it is emphasized that childhood stuttering can be accompanied by aspects of ADHD . Likewise, children exhibiting signs of ADHD more frequently display speech disfluencies than their peers. It is suggested that children with stuttering and those without stuttering will display different profiles in terms of temperament, certain aspects of ADHD, and some types of anxiety. In addition, it is to be expected that there will be some correlations between these variables in children who stutter. However, it is not possible to draw definite conclusions about this issue that could be generalized to all children who stutter. Furthermore, there are very few studies that deal with combinations of these variables .

Official Title
-----------------
Prevalence of Stuttering in Children With ADHD at Sohag University Hospital

Conditions
-----------------
ADHD Children With Stuttering

Intervention / Treatment
-----------------
* Diagnostic Test: : Conners rating scale-Stanford-Binet Intelligence Scales- stuttering severity index third edition (SSI-3) .


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All children with ADHD Exclusion Criteria: 1-Children ageed below 6 years old. 2- children with ADHD with other behavioral and neurological disorders.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: : Conners rating scale-Stanford-Binet Intelligence Scales- stuttering severity index third edition (SSI-3) .|Questionaire tests for ADHD -IQ-Stuttering severity assessment|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of stuttering in ADHD children | assessment of stuttering in ADHD children | 1 year |
Infant Microbiome in Diaper Rash

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the microbiome composition of infant's (9-12 month) skin experiencing diaper rash in order to determine if the onset and severity of erythema associated with diaper rash is influenced by the type of bacteria colonizing the skin.

Official Title
-----------------
An Exploratory Study to Evaluate the Microbial Consortia of Infants (9-12 Months) Experiencing Diaper Rash and When Healthy

Conditions
-----------------
Diaper Rash

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants aged 9-12 months with mild to moderate diaper rash Exclusion Criteria: Use of topical or oral antibiotics or antifungals within the past 4 weeks. Use of zinc-containing diaper rash creams within 48 hours first sample Immunocompromised

Ages Eligible for Study
-----------------
Minimum Age: 9 Months
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Operational Taxonomic Units (OTUs) of microbes present on skin |  | Change from Baseline at Day 14 | 
| Relative abundance of microbes present on skin measured in picograms of DNA |  | Change from Baseline at Day 14 |
The Role of Perfusion Index in Children

Study Overview
=================
Brief Summary
-----------------
The purpose of our study is to test the usability of the perfusion index in evaluating the success of the peripheral nerve block applied under sedation in children.

Official Title
-----------------
The Role of Peripheral Perfusion Index in Evaluating the Success of Peripheral Nerve Block in Children Under Sedation

Conditions
-----------------
Perfusion Index

Intervention / Treatment
-----------------
* Diagnostic Test: perfusion index


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: will undergo elective upper limb surgery, 2- 10 years old, ASA I Exclusion Criteria: have regional anesthesia contraindications, allergic to local anesthetics, having an infection at the injection site patients who do not accept the procedure

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: perfusion index|To test the objective role of perfusion index in assessing the success of the peripheral nerve block in children under sedation.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| perfusion index | To test the objective role of perfusion index in assessing the success of the peripheral nerve block in children under sedation. | 6 months |
Upper Limb Functional Testing in Athletes

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to elaborate sports-specific normative data for different upper limb functional tests. About 250 sportspeople, aged between 14 and 35 years, and practicing an upper limb sport, will be recruited. They will performed some of the following tests, based on the sport they practice : Upper Quarter Y Balance Test Athletic Shoulder Test Single Arm Medicine Ball Throw Countermovement push-ups Closed Kinetic Chain Upper Extremity Stability Test Upper Limb Rotation Test Posterior Shoulder Endurance Test Seated Shot Put Test

Official Title
-----------------
Upper Limb Functional Testing in Athletes: Elaboration of Normative Data

Conditions
-----------------
Functional Performance

Intervention / Treatment
-----------------
* Other: Performance of different upper limb functional tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To practice an upper limb sport, at least 5 or 6 hours a week Exclusion Criteria: Shoulder pain, injury or surgery during the last 6 months

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Performance of different upper limb functional tests|The participants will have to perform 3 to 5 different upper libm functional tests, depends on the sport they practice.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score Upper Quarter Y Balance Test | the maximal distance, in centimeters, will be measured | through study completion | 
| Athletic Shoulder Test | maximal peak force, in Newton, will be measured, using a handheld dynamometer | through study completion | 
| Single Arm Medicine Ball Throw | maximal distance, in meters, will be measured | through study completion | 
| Closed Kinetic Chain Upper Extremity Stability Test | the maximal number of touches, in 15 seconds, will be measured | through study completion | 
| Upper Limb Rotation Test | the maximal number of touches, in 15 seconds, will be measured | a single measurement | 
| Posterior Shoulder Endurance Test | time until exhaustion (in seconds) | through study completion | 
| Seated Single Arm Shot Put Test | maximal distance, in meters, will be measured | through study completion | 
| Shoulder rotators isometric strength | maximal peak force will be measured in Newton, using a handheld dynamometer | through study completion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prevention, performance
Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
Dialysis patient could be more aspirin resistant than the general population based on data from chronic kidney disease patients

Detailed Description
-----------------
We will try to describe the profile of aspirin resistant patient in hemodialysis patients

Official Title
-----------------
Prevalence of Aspirin Resistance in Hemodialysis Patients

Conditions
-----------------
Aspirin Resistance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all hemodialysis patients on aspirin Exclusion Criteria: low platelets <100.000 coagulopathy, bleeding disorders patient on plavix

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aspirin Resistance in Hemodialysis patients |  | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aspirin resistance, aspirin resistance in hemodialysis patients